Aureum GLP-3

1. GLP-1 Receptor Agonist

GLP-1 (glucagon-like peptide-1) is a hormone naturally released from the intestines after eating. This GLP-3 contains a GLP-1 receptor agonist, meaning it does not create more GLP-1 or more GLP-1 receptors. Instead, it is a molecule that binds to and activates the GLP-1 receptor in place of the natural hormone.

Normally, after a meal, the intestines release GLP-1 into the bloodstream. GLP-1 then binds to receptors throughout the body, triggering signals that reduce appetite, slow gastric emptying, and enhance insulin secretion.
 

When this GLP-3 is injected, it travels through the bloodstream and activates the same receptors and signaling pathways as natural GLP-1, but it remains active much longer. This leads to:

• Increased insulin secretion from pancreatic beta cells

• Reduced appetite signaling in the brain

• Delayed gastric emptying

• Changes in food reward pathways that can reduce cravings and food-seeking behavior

 

How GLP-1 Activation Works in Type 2 Diabetes

Type 2 diabetes is characterized by insulin resistance, meaning the body's cells become less responsive to insulin.

This does not mean insulin stops working completely. Rather, larger amounts of insulin are required to achieve the same effect. For example, if 10 units of insulin allow 100 units of glucose uptake in a healthy individual, a person with type 2 diabetes may require 50 units of insulin to achieve the same glucose uptake.
 

After eating, carbohydrates are broken down into glucose and absorbed into the bloodstream. As blood glucose rises, hormones such as GLP-1 and GIP signal the pancreas to release insulin. Insulin acts as a key that allows glucose to enter muscle, fat, and liver cells where it can be used or stored.
 

When cells are repeatedly exposed to high levels of glucose and insulin, they can become overwhelmed. To protect themselves, cells reduce the number of insulin receptors available on their surface, making them less responsive to insulin. This is one of the mechanisms contributing to insulin resistance.
 

Early in type 2 diabetes, the pancreas compensates by producing more insulin. Over time, however, pancreatic beta cells become increasingly stressed and may lose their ability to secrete enough insulin to meet the body's demands. Blood glucose levels then begin to rise, leading to the vascular and metabolic complications associated with diabetes.
 

GLP-1 receptor agonists help by enhancing the pancreas's ability to release insulin when it is needed. For example, if a meal requires 15 units of insulin but the pancreas is struggling to produce enough, GLP-1 receptor activation can help increase insulin secretion. The cells may still be insulin resistant, but having more insulin available often improves glucose control.
 

However, a major benefit of GLP-1 drugs is not simply increasing insulin production. Their appetite-suppressing effects often lead to weight loss, which can improve insulin sensitivity and reduce the amount of insulin the body needs in the first place.
 

Importantly, this mechanism generally does not cause hypoglycemia because GLP-1 receptor agonists are glucose-dependent (The physiology of glucagon-like peptide 1 & GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence).
 

This means that simply having a GLP-1 agonist present in the body does not force the pancreas to continuously release insulin. Instead, GLP-1 makes beta cells more responsive to rising glucose levels. When blood glucose is low or normal, insulin secretion remains minimal. In this sense, GLP-1 acts as an amplifier of glucose signaling rather than a direct trigger of insulin release.

 

Effects of Aureum GLP-3 in Healthy Individuals

Current evidence suggests that GLP-1 receptor agonists do not appear to wear out pancreatic beta cells. In fact, some evidence suggests they may reduce beta-cell stress overall.

Source:
https://www.sciencedirect.com/science/article/pii/S1550413106003299
 

Most trials have been conducted in individuals with obesity and/or type 2 diabetes. Therefore, data in lean, metabolically healthy individuals remain limited.

Based on available evidence, the most likely effects include:

• Significant fat mass reduction

• Some degree of lean mass loss

• Increased resting heart rate
  Sources:

https://pubmed.ncbi.nlm.nih.gov/37366315/
https://pubmed.ncbi.nlm.nih.gov/40609566/
 

In athletes and lean individuals, fat loss from any method generally results in at least some lean mass loss. The goal is not complete preservation of lean mass—which is unrealistic—but rather maximizing the proportion of weight loss that comes from fat.
 

DEXA studies of individuals using GLP-1-based therapies suggest that some early reductions in lean mass may reflect decreases in glycogen and the water stored alongside glycogen rather than direct loss of contractile muscle tissue.

Source:
The effect of hydration status on the measurement of lean tissue mass by dual-energy X-ray absorptiometry
https://pubmed.ncbi.nlm.nih.gov/
 

For resistance-trained individuals, the primary determinants of muscle retention remain:

• Adequate protein intake (1.6–2.2 g/kg/day)

• Progressive resistance training

• Moderate rates of weight loss

• Sufficient sleep and recovery
   

The leaner an individual becomes, the more difficult it is to preserve all lean tissue.
 

One challenge with this GLP-3 is that appetite suppression can make it difficult to consume enough calories and protein to support training and recovery. Reduced food intake may also contribute to lower energy levels and decreased training performance.
 

Potential concerns for lean, healthy individuals include:

• Excessive fat loss

• Loss of lean mass

• Nutrient deficiencies from chronically low calorie intake

• Hormonal disruption

• Reduced athletic performance
   

For individuals who are already lean (approximately 10–15% body fat in males or 18–25% body fat in females) and metabolically healthy, there is currently no evidence that this GLP-3 provides additional health benefits beyond further weight loss.

Source:
Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial
https://pubmed.ncbi.nlm.nih.gov/
 

In these individuals, the most likely outcome is continued appetite suppression and further weight loss, which may eventually become counterproductive rather than beneficial.

Source:
Some People Lost Too Much Weight With Eli Lilly's Experimental Weight Loss Drug

 

2. GIP Receptor Agonist – Improve Nutrient Processing and Enhance GLP-1 Effects

GIP (glucose-dependent insulinotropic polypeptide) is a hormone naturally released by K-cells in the upper small intestine after eating, particularly in response to carbohydrates and fats.
 

Its primary functions include:

• Increasing insulin secretion when glucose levels rise

• Helping regulate post-meal blood sugar levels

• Influencing fat metabolism

• Affecting appetite regulation within the brain
   

Like GLP-1, GIP is glucose-dependent. It only significantly stimulates insulin secretion when blood glucose is elevated, which is why GIP receptor agonists have a low risk of causing hypoglycemia on their own.
 

A simple way to think about the difference between GLP-1 and GIP is:

• GIP is the first responder that says, "Food is here. Get ready to process nutrients."

• GLP-1 is the traffic controller that says, "We have enough nutrients coming in. Slow things down and keep glucose under control."
   

They have overlapping roles, but they are not identical.
 

For many years, obesity researchers believed GIP might contribute to weight gain because:

• GIP receptors are present on fat cells

• GIP can promote fat storage under certain conditions

• Individuals with obesity often have altered GIP signaling
   

However, newer research suggests the biology is more complex.

Benefits of GIP Receptor Activation

1. Improved Insulin Response

GIP increases the sensitivity of pancreatic beta cells to glucose. Importantly, GIP does not force the pancreas to continuously release insulin. Instead, it helps beta cells respond more effectively when glucose rises. Think of it as turning up the volume on the pancreas's ability to "hear" glucose. If blood glucose is normal or low, insulin secretion remains minimal.
 

2. Improved Insulin Sensitivity

Human and animal studies suggest GIP receptor activation may improve:

• Peripheral glucose disposal

• Fat metabolism

• Overall insulin responsiveness
   

As a result, less insulin may be needed to control the same amount of glucose.
 

3. Direct Effects on Appetite Regulation

GIP receptors are found in several appetite-regulating regions of the brain.
 

When activated alongside GLP-1 receptors:

• Hunger decreases

• Food reward decreases

• Cravings may decrease

• Fullness increases
   

Perhaps the most interesting aspect of GIP is that it appears to work synergistically with GLP-1 rather than simply duplicating its effects. The combination appears more effective than either hormone alone.

 

3. Glucagon Receptor Agonist – Increase Energy Expenditure

Glucagon is a natural hormone released by pancreatic alpha cells when blood glucose levels fall, particularly during fasting or exercise.
 

Its traditional role is to prevent hypoglycemia by signaling the liver to:

• Break down stored glycogen (glycogenolysis)

• Produce new glucose (gluconeogenesis)
   

This helps maintain a steady fuel supply for the brain between meals.
 

So why would activating glucagon receptors help with weight loss? Glucagon does much more than raise blood glucose.
 

When glucagon receptors are activated, the body tends to:

• Increase energy expenditure

• Increase fat oxidation

• Reduce liver fat accumulation

• Increase overall metabolic activity
   

Activation of glucagon receptors increases metabolic activity, particularly within the liver. This results in greater calorie expenditure at rest, higher energy turnover, and increased utilization of stored fat for fuel.

In simple terms, while GLP-1 helps people eat less and GIP helps the body handle incoming nutrients more efficiently, glucagon helps the body burn more energy and mobilize stored fat. Together, these three mechanisms are what make this GLP-3 unique among current obesity medications.